Cybin Inc. CYBN Archives - Page 14 of 18

TuesdayOct 19, 2021 10:12 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin’s research and development team has completed 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. More than 50 novel compounds have been evaluated to date through collaborations with experienced contract research organizations for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding and safety to…

TuesdayOct 12, 2021 10:47 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. According to the update, the application, governed by the Patent Cooperation Treaty (“PCT”), brings the potential to obtain patent coverage in 153 countries. “The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Doug Drysdale, the company’s CEO. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading…

MondayOct 11, 2021 1:08 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://ibn.fm/NCORl). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reads a recent article quoting a Yale Daily News publication titled “Yale Researchers Discover Healing Effects of Psychedelic Drug.” In the piece published…

FridayOct 08, 2021 11:29 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions

Cybin names Dr. Amir Inamdar as chief medical officer for European operations The company appoints Dr. Geoff Varty as head of research and development Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made key additions and changes (https://ibn.fm/0GBMQ). Most recently the company has appointed two new executives and announced internal promotions to continue strengthening its leadership team. Cybin has named Dr. Amir Inamdar as chief medical…

ThursdayOct 07, 2021 11:54 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Achievement of Adelia Milestones

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as “Year 2 Q1 (i)-(iii).” According to the update, the milestones were contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly controlled subsidiary of Cybin, and all previous shareholders of Adelia. Per the terms of the agreement, Class B common shares in the capital of the acquiror shall be issued to Adelia shareholders, in satisfaction…

FridayOct 01, 2021 10:10 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the new head of research & development. In addition, the company has made some internal promotions, naming Lori Challenger as chief compliance, ethics & administrative officer and Robert Mino as general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug-development experience, Inamdar has deep expertise in progressing numerous drugs from preclinical development…

MondaySep 27, 2021 11:53 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation

WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19 People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection Cybin is on a mission to revolutionize mental healthcare A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental health, which has been rocked by the COVID-19 pandemic, is only increasing (https://ibn.fm/hzmXq). Cybin (NEO: CYBN) (NYSE American: CYBN) is focused on meeting that need and is committed to finding even more effective…

MondaySep 27, 2021 10:24 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present in Two Upcoming Investor Conferences

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two upcoming investor conferences. The company announced that CEO Doug Drysdale will be presenting virtually in a fireside chat during the Cantor Virtual Global Healthcare Conference and, during the Benzinga Healthcare Small Cap Conference, Drysdale will be presenting and participating in a panel discussion. The Benzinga conference is scheduled for Thursday, Sept. 30, 2021, and Drysdale’s presentation is scheduled for 12:15 p.m. ET. According to the announcement, Drysdale will also be involved in a panel discussion titled “Addressing Mental Health through Emerging Therapies”…

FridaySep 24, 2021 1:28 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several milestones, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than CA$120 million. In addition, Cybin has started the next phase of its digital therapeutics platform, signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc to establish Mental Health Centers of Excellence, as well as commenced scaling up its…

TuesdaySep 14, 2021 2:03 pm

QualityStocksNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Recent Acquisition Boosting Psychedelic Drug Development Program

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, announced its most recent acquisition and wholly controlled subsidiary, Adelia Therapeutics Inc., is already reporting success, having achieved certain milestones for the year. Cybin closed on the acquisition of Adelia late last year, with the company noting several key advantages gained through the transaction. According to a recent article, Cybin CEO Doug Drysdale stated that the company sees “this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s expertise across…

Site Search

Company Search

Tag: Cybin Inc. CYBN